Saliva test could unlock new blood disease treatments
NCT ID NCT02692872
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study screens healthy volunteers aged 18-39 who self-report African ancestry for alpha globin deletions, which cause alpha thalassemia. Participants provide a one-time saliva sample by mail or in person. The goal is to learn how these genetic changes affect blood vessels, which may help develop new treatments for blood disorders like sickle cell disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this screening could help researchers develop new treatments for blood diseases like sickle cell disease.
- What could go wrong
- This is an observational screening study, not a treatment trial. It only collects saliva samples and does not test any therapy, so it cannot directly lead to a cure or treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.